Biopharmaceutical companies are constantly evaluating new methods for mammalian cell line development that offer benefits such as shorter time lines, improved consistency, higher monoclonal antibody (mAb) production, better genetic stability and increased flexibility. Each of these advantages extends a potentially large cost benefit to companies as their recombinant protein products move from development into the clinic, and finally on to commercial launch1. In this context, sophisticated chemometric software packages show great potential in enhancing process knowledge and providing optimised control of these complex and challenging processes.
|Number of pages||6|
|Journal||European Pharmaceutical Review|
|Publication status||Published - 13 Jun 2013|
- mammalian cell line
- multivariate data analysis
- fault diagnosis